Biotechnology sector performed well on both public and private markets. Large public biotech stocks continued to climb while smaller stocks remained leveled. Private financing deal flow increased substantially, albeit leaving early stage start-ups behind. Biotech sector experienced an overall increase in VC activity during 2Q 2013 and after much less inspiring first quarter. The comeback of VC funding was consistent with strong public markets as well as high, 13, number of completed Life Sciences IPO transactions.
Purchase Accounting Valuation Benchmarking
Valuations of IP and intangible assets are complex and often unintuitive. Purchase price allocations (“PPAs”) or stand-alone IP valuations require esoteric financial models, hypothetical assumptions, and speculative projections. It is often difficult to gain comfort with a 50-100-page bespoke valuation report. Studying PPAs reported by public companies to the SEC may help. We analyzed 3,000+ PPAs reported since 2015 across
August 17, 2026
